# Fengxun Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fengxun-biotechnology

- Industry: Biotechnology
- Headquarters: Nantong, China
- Latest round: Series A (Sep 22, 2025)
- Investors on record: 4

## About

Founded in 2025 and based in Nantong, China, Fengxun Biotechnology focuses on advancing biotechnology research with applications in medical detection and inspection. The company develops innovative solutions to address healthcare testing needs by integrating biotechnology with applied science.

In July 2025, Fengxun Biotechnology closed a venture funding from new investor Lotus Capital. In September 2025, Fengxun Biotechnology closed series A funding from new investors Peakview Capital, Legend Capital, Casstar Capital and Hongfeng Venture. 

The company provides research and development in biotechnology-driven testing technologies. Its work includes the development of inspection systems and related applications aimed at improving diagnostic accuracy, efficiency, and reliability across healthcare and biotechnology fields. The company generates revenue from biotechnology research services, medical testing technology development, and healthcare-related application solutions.

The series A funding will be used by the company to accelerate product development and market promotion, further enhancing the company's competitiveness in the medical testing field.

## Funding rounds

- Series A, Sep 22, 2025 — Legend Capital, Casstar Capital, Peakview Capital, Hongfeng Venture

## Investors

- Legend Capital — Series A
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Series A
- Peakview Capital — Series A
- Hongfeng Venture (https://capitalatlas.ai/funds/hongfeng-venture) — Series A